Unknown NA INTERVENTIONAL 2-arm NCT01065727

Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis (IQUALYSEP)

Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis

Sponsor: Rennes University Hospital

Conditions Multiple Sclerosis

Interventions mitoxantrone - immunomodulator natalizumab

Updated 6 times since 2017 Last updated: Nov 30, 2012 Started: Feb 28, 2010 Primary completion: Feb 29, 2016 Completion: Feb 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Multiple Sclerosis, this trial is ongoing. The trial is conducted by Rennes University Hospital and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Mar 2019 — Jan 2021 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jun 2018 — Mar 2019 [monthly]

Recruiting NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting NA

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rennes University Hospital

Data source: Rennes University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brest, France
• Rennes, France